Hospital and physician-hospital alignment, but not loyalty, are predictors of integrated electronic health record adoption by admitting physicians in an integrated system.
Self-empowering team resource management, when aided by information technology, appears to help reduce adverse drug events in primary care offices.
A continuous quality improvement program, based on Lean concepts and including architectural, managerial, and organizational features, allows the emptying of emergency department corridors and the improvement of time interval measurements/quality indicators.
Value-based insurance design for prescription drug coverage increases drug adherence in patients with chronic disease, though their effect on clinical outcomes and health spending remain uncertain.
This mixed-methods study evaluated hospitalized patients’ and family members’ perceived communications mismatches and their calls for transparent real-time information and potential 21st-century solutions.
This study examines the feasibility and utility of using administrative claims from commercial health plans to identify children with chronic conditions in a statewide registry.
Alternative payment models (APMs) introduce value-based incentives for greater hospital health information exchange (HIE) engagement. We find that APM participation is associated with lower HIE volume and greater HIE diversity, breadth, and depth.
Acute sinusitis is a common acute illness and offers an opportunity to eliminate low-value care. The authors describe current practices, comparing primary care, urgent care, and the emergency department.
This scoping review found 350 articles that discuss US health insurance providers’ use of patient-reported outcomes about health-related quality of life.
At 1 year after Hurricane Katrina, the health burden of enrollees increased significantly more versus a comparison group. Emergency department visits and hospitalizations remained elevated.
The availability of biosimilar products may improve access to healthcare by increasing the number of therapeutic options available at potentially lower costs. As of April 2019, 18 such biological products had been approved by the FDA, including 4 biosimilars for trastuzumab, 3 each for infliximab and adalimumab, 2 each for pegfilgrastim and filgrastim, and 1 each for rituximab, epoetin alfa, bevacizumab, and etanercept. The pace of approvals has accelerated, from the first indication for a filgrastim biosimilar in 2015 to 3 approvals in 2016, 5 in 2017, and 9 through early 2019, 7 of which were announced in the 2018 calendar year.
Evaluation of cancer patients’ quality of life at admission enabled improvement of their satisfaction with received care at discharge.
From 2001 to 2011, the US Food and Drug Administration approved 9 single-enantiomer drugs with racemic precursors. None showed pre-approval evidence of improved efficacy over the racemic precursor.
Patient-reported outcomes, through the use of new technological advances, can be successfully integrated into routine orthopedic practice and shared across distinct institutions.
Proactive identification of cognitive impairment and compensatory destigmatized patient/familial psychoeducation regarding “forgetfulness” in hospitalized patients with congestive heart failure may reduce readmission rates substantially.
Racial and ethnic differences in hip fracture incidence and mortality outcome were observed within a diverse population of older men, with lower rates of both among Asians.